Table 3.
Terminal half-lives of fluticasone after intravenous administration and after inhalation via Diskus and pMDI (only healthy subjects).
| Dosing regimen | Subjects | Diskus (h) | pMDI (h) | Intravenous (h) |
|---|---|---|---|---|
| Single dose | Healthy | 11.4 (8.4–17.5) | 12.8 (7.1–41.4) | 12.7 (6.8–29.0) |
| With asthma | 9.4 (3.4–17.7) | – | 12.0 (7.1–19.5) | |
| Total | 10.7 (3.4–17.7) | – | 12.5 (6.8–29.0) | |
| Repeated dosing | Healthy | 11.1 (8.3–15.4) | 12.4 (8.1–18.9) | – |
| With asthma | 11.2 (9.9–14.6) | – | – | |
| Total | 11.1 (8.3–15.4) | – | – |
Values are given as geometric means (range).